Brief: Puma Biotechnology Receives FDA Orphan Drug Designation For Alisertib For The Treatment Of Small Cell Lung Cancer
21/09/2023 23:31
Puma Biotechnology Inc PBYI.O :
* PUMA BIOTECHNOLOGY RECEIVES FDA ORPHAN DRUG DESIGNATION
FOR
ALISERTIB FOR THE TREATMENT OF SMALL CELL LUNG CANCER
* PUMA BIOTECHNOLOGY INC - ANTICIPATES INITIATING PHASE II
TRIAL
IN SECOND HALF OF 2023
Source text for Eikon: ID:nBw9LRklXa
Further company coverage: PBYI.O
Recent news on Puma Biotechnology
See all newsBrief: Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(C)(4)
Brief: Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
Puma Biotechnology Inc reports results for the quarter ended June 30 - Earnings Summary
Corrected: Puma Biotechnology lifts 2026 outlook as Q2 revenue rises on NERLYNX demand
Brief: Puma Biotechnology Q2 Adjusted EPS USD 0.2